The Business Brew cover image

Peter Mantas - The Potential Opportunity in Life Sciences

The Business Brew

CHAPTER

Valuation of Preclinical Companies

This chapter discusses the valuation of preclinical companies in the life sciences industry, highlighting recent changes in interest rates impacting the biotech sector. The speaker shares their perspective on the inflation reduction act, the potential value of tool makers in biotech, and the challenges faced by the industry.

00:00
Transcript
Play full episode

Remember Everything You Learn from Podcasts

Save insights instantly, chat with episodes, and build lasting knowledge - all powered by AI.
App store bannerPlay store banner